More from EHA: latest Acute Leukemia scientific developments

September 12, 2020

“With the explosive development of genetic information and new targeted and non-targeted therapies, it’s not surprising that this year’s EHA25 contains a great number of important submissions regarding biological mechanisms, diagnostics, and new therapies.”

Gunnar Juliusson, member EHA25 Scientific Program Committee Advisory Board.

Not to be missed: